Diversity and Equity Are Critical to the Work We Do
Systemic racism is as real as any disease.
The biopharmaceutical industry is committed to driving real change and improving health outcomes for patients in underserved communities.
Our Commitment to Equity
Equity is critical to the health and well-being of Black and Brown communities, and it remains essential to a robust ecosystem of innovation. America’s biopharmaceutical companies are pushing for necessary systemic and long-term change to better meet the needs of Black and Brown America.
Our Continued Commitment to Industry Change
We’re working with patients, community groups and policymakers to address
social determinants of health and to drive proactive research that expands
data collection and improves health outcomes.
Mobile CTA: (shows in EE only)
We’re committed to working toward a clinical trials infrastructure that addresses health disparities and closes the gap in clinical trial diversity to better reflect the intended treatment population.
Mobile CTA: (shows in EE only)
Talent
We aim to grow the talent pool, create new pathways to our industry and foster more inclusive work environments so that our workforce better reflects census representation top to bottom and side to side.
Voices from Our Blog
Systemic racism is as real as
any disease and our industry
is not immune
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
Addressing data challenges to improve health equity
PhRMA will continue to
advocate for equity within our
industry
Three ways the pharmaceutical industry can positively impact health equity
Systemic racism is as real as
any disease and our industry
is not immune
Systemic racism is as real as
any disease and our industry
is not immune
PhRMA published our commitment to racial equity and inclusion in the New York Times as well as in DC-based, Black-owned newspapers the Informer and the AfroAmerican. This public declaration is an important milestone for our industry as we continue to take concrete steps to address systemic racism and work towards a more equitable future…
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. Outside of the novel coronavirus, major social issues have been brought to the forefront of public discourse. We understand that systematic racism is as real as any disease and...
Addressing data challenges to improve health equity
Addressing data challenges to improve health equity
The COVID-19 pandemic has shed light on the ways that systemic racism pervades nearly every facet of life – especially within our health care system. The biopharmaceutical industry is dedicated to tackling these issues head-on and addressing health disparities that disproportionately affect communities of color and other underserved communities.
PhRMA will continue to
advocate for equity within our
industry
PhRMA will continue to
advocate for equity within our
industry
When I first started at PhRMA two and a half years ago, our organization was just starting to talk about how we could increase and activate our commitment to diversity & inclusion (D&I). As senior director of talent acquisition, some of my first tasks were to build an inhouse recruiting team and develop a D&I strategy for the organization…
Three ways the pharmaceutical industry can positively impact health equity
Three ways the pharmaceutical industry can positively impact health equity
“Creating a trusted partnership between the biopharmaceutical industry and communities of color will not happen overnight. It will take a sustained commitment to establish meaningful relationships that move us from health disparity to health equity.
I urge you to follow the progress at PhRMA.org/Equity.”
Reports and Agency Comments
PhRMA Awards Nearly $350K to Community-based Projects to Address Inequities in Diagnosis, Treatment, and Adherence
Inequities in health status and outcomes among racial and ethnic groups often are rooted in community-level factors. Recognizing that each community faces unique barriers, PhRMA established the Collaborative Actions to Reach Equity (CAREs) grant program in April 2020. To date, awards have supported research and efforts to advance equity across the country - and 2021 grantees have been finalized.
PhRMA Submits Comments to the Congressional Social Determinants of Health Caucus
The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to comment on the Congressional Social Determinants of Health Caucus Request for Information (RFI), which seeks feedback on challenges and opportunities related to social determinants of health. Consistent with our priority of building a more just, equitable health care system, PhRMA believes that diversity, equity, and inclusion are essential to the discovery of new medicines and that people of all ethnic and racial backgrounds should have equitable access to treatment.
Comments to OMB on Methods and Leading Practices for Advancing Equity for Underserved Communities Through Government
PhRMA appreciates the opportunity to comment on OMB's Request for Information (RFI), “Methods and Leading Practices for Advancing Equity and Support for Underserved Communities Through Government,” which was published in the Federal Register on May 5, 2021.
Comments on CMS Request for Information on Closing the Health Equity Gap in CMS Quality Programs
PhRMA appreciates the opportunity to comment on proposed Medicare FY 2022 Inpatient Psychiatric Facilities Prospective Payment System and Quality Reporting Updates for Fiscal Year Beginning October 1, 2021, specifically in response to the Request for Information on Closing the Health Equity Gap in CMS Quality Programs.
Medicines in Development for Health Equity 2021 Report
Today, more than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities.
PhRMA Comments to NIH Request for Information on Advancing and Strengthening Racial Equity in the Biomedical Research Workforce
The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to comment on the NIH’s request for information on approaches to advance racial equity, diversity, and inclusion within all facets of the biomedical research workforce and expand research to eliminate health disparities and foster equity.
A Message from PhRMA President and CEO Stephen J. Ubl
Pathways to Success in Biopharma – Virtual Graduate Summit and Career Expo
Want to hear from biopharmaceutical leaders and learn more about what it’s like to work in the industry? PhRMA will be hosting a two-day, free virtual summit for graduate students, postdoctoral trainees, faculty, PhRMA member companies and other community partners to learn about career pathways and increasing diverse talent within the industry.
Follow Our Progress as We Push for Change
Subscribe below for regular email updates as we push for necessary systemic and long-term change to improve health outcomes for underserved communities.
